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Abstract
Background and aims—While the prevalence of major depression is elevated amongst 
cannabis users, the role of genetics in this pattern of comorbidity is not clear. This study aimed to 
estimate the heritability of cannabis use and major depression, quantify the genetic overlap 
between these two traits, and localize regions of the genome that segregate in families with 
cannabis use and major depression.
Design—Family-based univariate and bivariate genetic analysis.
Setting—San Antonio, Texas, USA
Participants—Genetics of Brain Structure and Function study (GOBS) participants: 1,284 
Mexican-Americans from 75 large multi-generation families and an additional 57 genetically 
unrelated spouses.
Measurements—Phenotypes of lifetime history of cannabis use and major depression, 
measured using the semi-structured MINI-Plus interview. Genotypes measured using ~1M single 
nucleotide polymorphisms (SNPs) on Illumina BeadChips. A sub-selection of these SNPs were 
used to build multipoint identity-by-descent matrices for linkage analysis.
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Findings—Both cannabis use (h2=0.614, p=1.00×10−6, SE=0.151) and major depression 
(h2=0.349, p=1.06×10−5, SE=0.100) are heritable traits, and there is significant genetic correlation 
between the two (ρg=0.424, p=0.0364, SE=0.195). Genome-wide linkage scans identify a 
significant univariate linkage peak for major depression on chromosome 22 (LOD=3.144 at 2cM), 
with a suggestive peak for cannabis use on chromosome 21 (LOD=2.123 at 37cM). A significant 
pleiotropic linkage peak influencing both cannabis use and major depression was identified on 
chromosome 11, using a bivariate model (LOD=3.229 at 112cM). Follow-up of this pleiotropic 
signal identified a SNP 20kb upstream of NCAM1 (rs7932341) that shows significant bivariate 
association (p=3.10×10−5). However this SNP is rare (7 minor allele carriers) and does not drive 
the linkage signal observed.
Conclusions—There appears to be significant genetic overlap between cannabis use and major 
depression among Mexican-Americans, a pleiotropy that appears to be localized to a region on 
chromosome 11q23 that has been previously linked to these phenotypes.
Introduction
Cannabis is one of the most commonly used psychoactive substances globally, 
approximately 181.8 million people used the drug in 2013 [1]. In the same year, it was 
estimated 43.7% of the US population had tried cannabis at some point and 4.2 million 
Amercians reached criteria for cannabis abuse or dependence [2]. There is substantial 
evidence from a number of different populations indicating that cannabis use is associated 
with a modest but significant increase in risk of major depression (MDD); the degree of risk 
is also known to increase as the level of cannabis use increases [3–5]. Furthermore, for 
patients with MDD, comorbid drug use and abuse is associated with a poorer prognosis [6].
There is debate over the mechanism that underlies the comorbidity between cannabis use 
and MDD [7]. The self-medication hypothesis proposes that depression leads to cannabis 
use as a method to manage depressive symptoms [8,9], but there is longitudinal evidence 
suggesting that cannabis use younger in life increases the likelihood of later depression 
[3,10]. A third hypothesis is that there are common genetic etiological factors that increase 
the risk for both traits. If genes that exert pleiotropic effects on both cannabis use and MDD 
can be identified, this will provide an insight into the neurobiological basis of the connection 
between these two disorders.
Both MDD and cannabis use are well-established as heritable traits; for MDD 31-42% of 
liability to the disorder is due to additive genetic factors [11]. The heritability for initiation 
of cannabis use has been estimated at 40-48%, whilst cannabis abuse/dependence show a 
higher heritability of 51-59% [12]. Considering the relationship between these two heritable 
traits, reports from family studies show a significant role for genetic factors in the 
comorbidity of MDD and cannabis dependence [13–15], and a recent GWAS (genome-wide 
association study) reported SNP-based evidence of pleiotropy in European-American, 
although not African-American samples [16].
However, identifying the specific genes involved in MDD and cannabis has proved complex. 
The largest GWAS in MDD published to date found no significant associations [17]. This 
may be due to lack of statistical power, but heterogeneity could play an important role. If so, 
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increasing sample size through the combination of a large number of different cohorts may 
increase heterogeneity and compound the problem further. A recent study using low 
coverage genome-sequencing focused specifically on Han Chinese females with recurrent 
MDD, and identified two replicated loci on chromosome 10 [18]. Alternatively, family-
based analyses can also reduce heterogeneity, as the analysis is constrained for genetic 
background and environmental exposures [19]. Indeed using linkage methods a genome-
wide linkage signal on 3p has been identified in two independent cohorts [20,21], although 
the specific variants underlying this signal remain elusive.
Cannabis use has been less extensively studied from a genetic perspective; but there has 
been recent success in identifying significant associations in a GWAS of cannabis 
dependence symptoms (on chromosomes 3, 8 and 10, [16]). Further, gene-based tests 
showed significant associations with cannabis use and four genes (NCAM1, CADM2, 
SCOC and KCNT2) in a meta-analysis [22]. This meta-analysis also observed SNP-based 
heritability estimates (between 13-20%) lower than twin-based estimations [22], possibly 
indicating rare variants are also important in this phenotype. Nevertheless, linkage studies 
(which are ostensibly able to capture both common and rarer variation due to the family-
based design) are yet to identify replicated linkage signals for cannabis use [23–25].
Despite the reports of shared genetic influences outlined above, to our knowledge there has 
been no previous research investigating the chromosomal loci underpinning the comorbidity 
between cannabis use and MDD on a genome-wide scale. To do this, here we use an 
extended pedigree sample. We apply bivariate linkage scans that not only allow the 
identification of pleiotropic loci influencing both cannabis use and MDD, but have also been 
shown to give increased power and localization for the mapping of correlated traits [26]. The 
identification of pleiotropic influences also allows us to focus on the neurobiological 
pathways shared between MDD and cannabis use, thus tackling the issue of phenotypic 
heterogeneity. These family-based methods also allow us to both decrease the genetic 
heterogeneity of the sample and capture rarer genetic variation. By using a randomly 
ascertained sample, we avoid the potential bias of clinically ascertained samples, where 
greater symptom severity and higher rates of comorbidity are likely to occur [27,28].
The individuals in our study are Mexican-American, representing a relatively understudied 
population. In the USA, Mexican-Americans make up approximately 64% of the Hispanic 
and Latino population, and approximately 11% of the total population [29]. In genetic terms, 
the sample shows admixture from European and Native American populations (with small 
proportions of West African ancestry) [30].
Aims
The aims of this study are 1) estimate the heritability of MDD and cannabis use within this 
sample, 2) quantify the genetic correlation between these two traits, 3) localize regions of 
the genome that segregate in families with MDD and cannabis use using univariate and 
bivariate linkage models to identify both specific and pleiotropic risk loci, 4) follow up any 
identified genome-wide significant linkage regions using available SNP data to try to 
localize the genetic signal further.
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Methods
PARTICIPANTS
The Genetics of Brain Structure and Function study (GOBS) consists of 1,284 Mexican-
Americans from 75 large multi-generation families (containing between 2-132 subjects, 
mean pedigree size=16.36, SD=19.41) and an additional 57 genetically unrelated spouses. 
The mean age of the sample was 46.08 years (SD=14.89, age range=18-97 years), and 
62.7% of the sample was female. Familial relationships are shown in Table 1. Stated 
pedigree relationships were confirmed using PREST and available autosomal markers [31].
SAMPLE
GOBS is a subset of the San Antonio Family Study cohort of individuals who were pseudo-
randomly ascertained with the constraints that participants must live within the San Antonio 
region, be Mexican-American in ancestry, and part of a large family (at least 6 1st degree 
relatives). Full recruitment details are available elsewhere [32,33]. All subjects provided 
informed written consent (as approved by Institutional Review Boards at the University of 
Texas Health Science Center San Antonio and Yale University) and the cohort have been 
actively participating in research for over 18 years.
MEASURES
PHENOTYPIC MEASURES—The semi-structured Mini International Psychiatric 
Interview Plus (MINI-Plus [34]) was administered to all participants. Further details on the 
MINI-Plus are in the Supplementary Materials. To assess cannabis use, participants were 
asked to whether they had taken cannabis more than once, in order to get high, to feel better 
or to change their mood. Measures refer to lifetime history of MDD and cannabis use.
GENOTYPIC MEASURES—Genotyping was performed following the Illumina Infinitum 
protocol, using Illumina BeadChips covering ~1 million SNPs, capturing approximately 
90% of the common variants in humans. This was either achieved using the 1M-Duo 
BeadChip (which covers ~1 million SNPs, n=714) or the HumanMap550 BeadChip (which 
covers ~550,000 SNPs) in tandem with a supplementary Human 450S BeadChip (n=570) to 
give matching content. Full quality control details given in the Supplementary Materials.
For linkage analysis, a subset of 28,387 SNPs were selected using genotypes from 345 
founders. These SNPs were selected in order to maximize the information content across the 
genome but avoid potential bias from linkage disequilibrium (LD) patterns [35]. Therefore 
SNPs were selected with a minimum spacing of 1KB and a MAF>5% and a LD limit of 
pairwise r2<0.0225 within a 100KB sliding window was used. Build NCBI36/hg18 was used 
for all SNP locations. The selected subset of SNPs gave an average of 7-8 SNPs per 
centimorgan (cM). Using these 28,387 SNPs, multipoint identity-by-descent matrices were 
constructed at each cM location, using a stochastic Markov Chain Monte Carlo procedure 
within LOKI [36].
STATISTICAL ANALYSIS—Within SOLAR [37], maximum likelihood decomposition 
methods were used to model the patterns of trait covariance between family members as a 
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function of genetic relationship, allowing the estimation of the genetic and environmental 
contributions to phenotypes within a family structure. As binary traits are used, the standard 
threshold model for dichotomous phenotypes was employed [38]. In the simplest case of 
univariate variance decomposition, the additive genetic contribution to a trait is signified by 
the heritability (h2). This was calculated for both cannabis use and MDD. To decompose the 
phenotypic covariation between the two traits, bivariate analyses were [39]; genetic 
correlations determine if there is evidence of shared genetic influences (pleiotropy) [26]. 
The covariates of age, age2, sex and the interactions between these were included in all 
analyses.
Genome-wide multipoint linkage analysis was then undertaken, to identify genetic loci 
involved in each phenotype. Using a model which incorporates the specific marker density 
and pedigree complexity of the sample [40]; it has previously been established in this sample 
that a LOD score >2.9 indicates a genome-wide significant linkage peak, whilst a LOD 
score over 1.67 is indicative of a suggestive peak (likely to occur by chance less than once 
per genome-wide scan [41]). For further details on the selection of these genome-wide 
thresholds, see Supplementary Materials. We conducted univariate linkage of cannabis use 
and MDD followed by a bivariate linkage scan to identify chromosomal locations 
influencing both traits. In additional to LOD scores, empirical p-values were also estimated 
via simulations for each model (see Supplementary Materials). To test whether any 
linkage peaks identified within this scan were truly bivariate in nature, nested models were 
compared to test whether the model could be explained in the absence of any shared genetic 
effect; that is where the co-occurrence of linkage peaks in the two traits occurred by chance 
[42]. This test is referred to as the “pleiotropy test”.
Finally, to follow-up any significant linkage signals, we performed measured genotype 
association (mga) analyses beneath significant loci, which in this case were defined as the 
interval of maximum LOD score–1 surrounding the linkage peak. SNPs within these loci 
were selected from the full set of ~1M SNPs available from the Illumina BeadChips, and 
tested for association using the mga test within SOLAR, where models include the fixed 
effect of the SNP as well as random effects of local and polygenic heritability. An additive 
genetic model was assumed, and the first four principal components of the GWAS data were 
included as covariates to account for population stratification. To test for significance, a 
likelihood ratio test was employed, comparing models where the genotype parameter is 
allowed to vary freely or is fixed to zero. Given patterns of LD, the pairwise correlations 
between SNPs were used to calculate the effective number of independent tests within each 
region (effSNPS, [43]) for an appropriate multiple-testing correction.
Results
DESCRIPTIVE STATISTICS AND TRAIT HERITABILITY
Details of cannabis use and MDD in the sample are shown in Table 2. Considering the 
relationship between the two phenotypes, 35.9% of cannabis users had comorbid MDD. This 
represents a modest but significant increase in the likelihood of MDD amongst cannabis 
users (OR=1.530, 95%CI=1.056-2.209, p=0.024). The two traits were both heritable and 
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showed significant genetic correlation with no evidence of environmental correlation (Table 
3 and 4).
UNIVARIATE GENOME-WIDE LINKAGE
Genome-wide multipoint linkage scans were conducted for both cannabis use and MDD. A 
suggestive linkage peak was identified for cannabis use (21q22, LOD=2.123, p=0.0004), 
whilst a significant linkage peak was identified for MDD (22q11, LOD=3.144, p<0.0001). 
Further details are within Table 3 and Figures 1&2.
To follow up the significant linkage signal for MDD, association analyses were performed 
for all SNPs underneath this 2.3MB peak. This region included 676 SNPs (effSNPs=423.27, 
adjusted p-threshold=1.21×10−4), but none showed significant association with MDD 
(minimum p-value observed=2.24×10−3).
BIVARIATE LINKAGE BETWEEN MDD AND CANNABIS USE
Genome-wide bivariate linkage models of cannabis use and MDD were then analyzed. One 
region of genome-wide significance was identified on 11q23 (LOD=3.229, p<0.0001). 
Within the 3.3MB region surrounding the peak, 1,166 SNPs were tested for bivariate 
association with cannabis use and MDD (effSNPs=613.75, adjusted p-threshold= 
8.36×10−5). One SNP exceeded this threshold; rs7932341 (A/C, n=7). This SNP is 
intergenic; it lies 20kb upstream from NCAM1 (neural cell adhesion molecule 1). When 
looking at the univariate associations for this SNP, suggestive association was seen for both 
traits when considered separately. See Table 4, Figure 3 & S4 for further details.
To test whether the identified SNP can account the linkage signal on chromosome 11, we 
repeated our linkage analysis, covarying for rs7932341. However, the linkage signal at 
112cM on chromosome 11 increased in significance (LOD=3.572). This indicates that 
rs7932341 is not driving our linkage signal; there may be additional variants within this 
region that are associated with cannabis use and MDD but are not captured on the SNP 
BeadChips.
Discussion
SUMMARY OF FINDINGS
We observe a significant relationship between cannabis use and MDD (OR=1.530 for MDD 
amongst cannabis users) and demonstrate significant genetic correlation between the two 
heritable traits. Localizing the chromosomal regions involved, a genome-wide significant 
linkage peak was observed for MDD at 22q11.1-q11.21, with a suggestive signal for 
cannabis use noted at 21q22.11-q22.12. Using a bivariate linkage model, a pleiotropic 
genome-wide significant trait locus was identified on 11q23.1-q23.2, which spans the 
NCAM1-TTC12-ANKK1-DRD2 gene cluster.
REPLICATION OF PREVIOUS FINDINGS
The heritability estimates [11,12], elevated incidence of MDD amongst cannabis users [3–5] 
and the shared genetic etiology [13,14,16] of these traits within our sample are consistent 
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with previous studies. The linkage results also show convergence with previous findings. 
First, the signal for MDD on chromosome 22 is within the location of 22q11.2 deletion 
syndrome, where hemizygous deletions of up to 3MB are associated with a range of 
symptoms including heart abnormalities, immune system dysfunction, developmental 
delays, and various psychiatric disorders especially schizophrenia [44]. Many of the genes 
located at this site of micro-deletion are brain-expressed genes [45] and a recent survey of 
1400 individuals with this deletion showed increased prevalence of psychiatric disorders, 
particularly schizophrenia, autism, anxiety and MDD [46]. However, using SNPs from the 
available genotype data, we are unable to localize this univariate linkage signal of MDD 
more precisely within our sample.
Second, the bivariate cannabis-MDD peak at 11q23 spans the NCAM1-TTC12-ANKK1-
DRD2 gene cluster. DRD2 encodes the D2 dopamine receptor and dopamine has previously 
been implicated in both MDD and addition phenotypes, via its role in motivation and reward 
[47] and the effects of abused substances (including cannabis) on dopamine levels in the 
nucleus accumbens [48,49]. NCAM1 encodes a brain-expressed cell adhesion protein [50], 
known to be involved in the development of the nervous system and neuroplasticity 
(important in learning and memory, as reviewed by [51]). This is pertinent for addiction, as 
it is posited to involve the subversion of reward-related learning and there is also evidence 
that addiction phenotypes alter expression levels of polysialylated NCAM in the brain [52–
54]. Similarly, depressive episodes have been linked to neuronal atrophy, whilst efficacious 
antidepressant treatment increases neurogenesis and enhances neural plasticity [55,56] and 
there is evidence that NCAM levels may be associated with MDD (and related behaviors) 
[57–59].
In terms of previous genetic evidence within this genomic location, DRD2 and in particular 
the DRD2 Taq1A polymorphism (rs1800497, located in the coding region of ANKK1 [60]) 
have been frequently interrogated in relation to substance use. However, candidate gene 
studies are known to be prone to type I errors. When systematic meta-analysis of the 
literature is conducted, evidence of association with substance use/abuse is equivocal; meta-
analyses looking at rs1800497 in relation to smoking [61,62] and alcohol [63,64] have been 
mixed, with effects possibly being population, gender or substance-specific.
Nevertheless, Gelernter and colleagues propose that there are multiple variants across the 
NCAM1-TTC12-ANKK1-DRD2 gene cluster that impact on addiction-related phenotypes 
(such as alcohol, nicotine and comorbid alcohol and drug dependence) in both African-
American and European-American samples [65–67]. In line with this, a meta-analysis by the 
International Cannabis Consortium [22] found that using a gene-based approach NCAM1 
(along with three other genes) showed significant association with lifetime cannabis use, 
although no individual SNP reached genome-wide significance thresholds. This is consistent 
with a number of variants within the gene influencing the complex trait of cannabis use.
Using association analysis to follow up the significant linkage signal, no evidence of 
association was found for the DRD2 Taq1A polymorphism (using univariate or bivariate 
models, p>0.25 in all cases), but we note a peak-wide bivariate association between a SNP 
in the region (rs7932341) and cannabis-MDD. The identified intergenic SNP is 20KB 
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upstream of NCAM1 and shows interesting population-specific variation. In this sample it is 
a rare SNP (n=7, estimated MAF=0.0016); using the 1000 Genomes Phase 3 data [68] we 
note that the minor allele is found within American admixture (MAF=0.01) and African 
(MAF=0.09) populations, but is not observed in Asian or European samples. These 
differences between populations highlight the importance of studying populations from a 
wide range of different ancestral backgrounds. Further analysis in our sample indicates this 
rare variant is not driving the linkage signal observed in this region, consistent with the 
presence of additional variants. As rs7932341 is both rare in this sample and does not drive 
the linkage signal, the observed association with this SNP should be considered tentative; 
replication attempts, particularly in populations where the variant is more common, would 
be of interest. Therefore, the bivariate linkage signal occurs in a previously highlighted 
region of interest for both MDD and cannabis use on chromosome 11. Nevertheless, 
additional work is needed to identify the relevant causal genetic variants involved.
SPECIFIC AND PLEIOTROPIC GENETIC INFLUENCES
Whilst we observe evidence of pleiotropic influences on cannabis use and MDD on 
chromosome 11, the univariate signals on chromosome 21 (cannabis use) and 22 (MDD) 
identified here appear to be phenotype-specific; LOD scores are very low (LOD<0.5) for the 
alternative phenotype. We cannot rule out the presence of pleiotropic effects that are too 
small to be detected in this sample, but the observed pattern suggests that the genetic 
architecture of cannabis use and MDD consists of a combination of phenotype-specific and 
shared genetic influences, where there are genetic loci that influence only MDD with no 
effects on cannabis use, and vice versa, as well as loci exerting pleiotropic effects on both 
phenotypes. This model would be in agreement with the pattern of genetic overlap between 
cannabis use and MDD, accounting for some but not all of the heritability of each trait.
Evidence of genetic correlation between cannabis use and MDD is not sufficient to 
determine the biological pathways involved in their comorbidity. Shared genetic etiology 
could reflect genes exerting effects on both cannabis use and MDD, or alternatively genetic 
influences could increase liability to one trait, which then in turn increases risk of the second 
trait. Identification of the specific genes involved offers a starting point to untangle these 
factors. Through our linkage and association analysis we have highlighted 11q23 as a region 
of interest. Further replication is needed, but once validated genes connected to both 
cannabis use and MDD are established, researchers will have a tool with which to 
investigate the underlying neurobiology and begin to determine the directionality of the 
relationship between these two phenotypes. We suggest that the picture is likely to be 
complex with multiple interacting pathways and a high degree of inter-individual 
heterogeneity.
STUDY LIMITATIONS
Whilst a number of our findings align well with previous literature, we do not replicate 
previous findings in MDD on chromosome 3p [20,21] or chromosome 10 [18]. Similarly, the 
highest linkage peak that we observe for cannabis use on chromosome 21 is not a region 
identified in prior genomic studies of cannabis-related phenotypes [16,23,25,69]. This may 
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be due sample differences in ancestry, phenotype definitions or limitations in statistical 
power. See Supplementary Materials for power calculations.
Nonetheless, there is evidence that rare variants play an important role in cannabis-related 
phenotypes [70] and so linkage studies are valuable in the search for the genetics 
underpinning cannabis use, as they are able to capture effects from both common and rare 
variants (in contrast to GWAS which focus on common SNPs). There is evidence that the 
heritability of cannabis phenotypes increases with the severity of use [12], so focusing on a 
more severe phenotype of cannabis dependence could be beneficial in identifying linkage 
regions. Nevertheless, the merits of a more narrowly defined phenotype must balanced with 
the associated decrease in available cases: in the case of the GOBS sample only 4.0% report 
cannabis dependence, whilst 13.2% report cannabis use.
Given the family-based design of the sample, when estimating the degree of genetic 
influence for traits, we are not able to disentangle environmental influences that make family 
members similar to each other (“shared environmental effects”) from genetic effects, as twin 
studies can. However, these shared environmental effects are less likely to inflate heritability 
estimates within a multigenerational extended pedigree sample such as GOBS [71] and this 
family study design enables the localization of trait loci.
Finally, we note that whilst the lifetime prevalence of cannabis use in this sample (13.2%) 
matches closely with that given for the USA in a recent United Nations report (13.7% [72]), 
the sample prevalence for MDD (33.8%) is greater than the ~17% estimated in US-based 
epidemiological studies [73,74]. Whilst US-based epidemiology surveys note that Hispanics 
generally have lower rates of psychiatric illness than the USA as a whole, as previously 
mentioned the term “Hispanic” encompasses a wide heterogeneity in bio-geographic 
ancestry. Factors such acculturation, relative social status and level of perceived 
discrimination are known to play an important role in variability in vulnerability to 
psychiatric illness within Hispanic minority subgroups [75–78]. Research focusing on 
understudied populations such as these are important in helping to build a understanding of 
vulnerability to psychiatric illness and how this may vary across the globe.
CONCLUSIONS
Genetic correlations between cannabis use and MDD indicate that the pattern of comorbidity 
between the two phenotypes is (in part) due to a shared genetic etiology. We identify a 
linkage signal for MDD on 22q11 as well as a pleiotropic locus on 11q23, which spans the 
NCAM1-TTC12-ANKK1-DRDR2 gene cluster. The genes within this region have 
previously been linked to both addiction and MDD phenotypes. Further work is need to 
confirm the causal variants within this locus, but we have identified genomic regions of 
interest that may act as a starting point for understanding the relationship between cannabis 
use and MDD, and the neurobiology underpinning their shared etiology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Upper panel: suggestive univariate linkage peak for cannabis use at 21q22.11- q22.12, 
logarithm of the odds (LOD) = 2.123. Horizontal black solid and dashed lines indicate 
significant and suggestive thresholds for LOD scores. Vertical dashed grey lines define the 
linkage region, using (maximum LOD-1) confidence interval. Lower panel: Genes within 
the 21q22.11-q22.12 suggestive linkage peak for cannabis use. Drawn using the UCSC 
Genome Browser
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Figure 2. 
Upper panel: significant univariate linkage peak for major depression at 22q11.1- q11.21, 
limit of detection (LOD) = 3.144. Horizontal black solid and dashed lines indicate 
significant and suggestive thresholds for LOD scores. Vertical dashed grey lines define the 
linkage region, using (maximum LOD-1) confidence interval. Lower panel: genes within the 
22q11.1-q11.21 significant linkage peak for major depression. Drawn using the UCSC 
Genome Browser
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Figure 3. 
Upper panel: significant bivariate linkage peak for cannabis use-major depression at 
11q23.1-q23.2, limit of detection (LOD) = 3.229, pleiotropy test $B&mp;V (J2 (1) = 9.77, P 
= 8.86 $B!_(J 10-4). Horizontal black solid and dashed lines indicate significant and 
suggestive thresholds for LOD scores. Vertical dashed grey lines define the linkage region, 
using (maximum LOD-1) confidence interval. Lower panel: genes within the 11q23.1-q23.2 
significant bivariate linkage peak for cannabis use-major depression. The position of single 
nucleotide polymorphism (SNP) s7932341 is also shown. Drawn using the UCSC Genome 
Browser
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TABLE 1
RELATIONSHIPS WITHIN PEDIGREES
No. of pairs Relationship
1284 Self
1 Identical sib-pair
841 Parent-offspring
917 Siblings
185 Grandparent-grandchild
1590 Avuncular
176 Half siblings
6 Double 1st cousins
2764 3rd degree
3103 4th degree
2180 5th degree
1062 6th degree
563 7th degree
130 8th degree
9980 Unrelated
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TABLE 2
SAMPLE DEMOGRAPHICS
Prevalence
N % of sample Mean age in years (SD) % female
Cannabis Use 170 13.2% 36.32 (11.56) 40%
MDD 434 33.8% 46.85 (13.15) 73.5%
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TABLE 3
RESULTS FROM UNIVARIATE ANALYSES
Heritability Linkage
H2 P value SE Location LOD
Cannabis Use 0.614 1.00×10−6 0.151 Chr 21, 37cM 2.123
MDD 0.349 1.06×10−5 0.100 Chr 22, 2cM 3.144
Significant heritability and linkage results highlighted in bold
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TABLE 4
RESULTS FROM BIVARIATE ANALYSES
Analysis
Bivariate model Univariate models
Cannabis use-MDD Cannabis use MDD
Genetic correlation ρg=0.424, p=0.036, SE=0.195
Environmental correlation ρE=−0.086, p=0.655, SE=0.195
Linkage at Chr 11, 112cM LOD 3.229 2.028 1.545
Association at rs7932341
Pval 3.10×10−5 5.75×10−4 1.86×10−3
Beta Cannabis; −2.638
MDD; −4.89
−2.554 −5.275
(Univariate findings are also shown at the location of interest)
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